Title: METHOD OF SCREENING FOR POTENTIAL ANTI-BACTERIAL AGENTS

Abstract: The invention provides a method of screening for potential anti-bacterial agents being antagonists of one or both of the transglycosylase and the transpeptidase enzymes involved in peptidoglycan biosynthesis in bacteria. The method is suitable for high throughput screening of compounds.
METHOD OF SCREENING FOR POTENTIAL ANTI-BACTERIAL AGENTS

The present invention relates to a method of screening for potential anti-bacterial agents.

Peptidoglycan is a major component of the bacterial cell wall that gives the wall its shape and strength. It is unique to bacteria and is found in all bacteria, both gram-positive and gram-negative. Peptidoglycan is a polymer of glycan strands that are cross-linked through short peptide bridges. It consists of alternating β1-4 linked residues of N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc). A pentapeptide chain is attached to MurNAc (MurNAc-pentapeptide) and cross-linking occurs between these peptide chains.

Biosynthesis of peptidoglycan can be divided into three stages: firstly, synthesis of the precursors in the cytoplasm, secondly, transfer of the precursors to a lipid carrier molecule and, thirdly, insertion of the precursors into the cell wall and coupling to existing peptidoglycan.

The precursors synthesised in the cytoplasm are the sugar nucleotides: UDP-N-acetyl-glucosamine (UDP-GlcNAc) and UDP-N-acetylmuramylpentapeptide (UDP-MurNAc-pentapeptide).

The second stage, which occurs in the cytoplasmic membrane, is catalysed by two enzymes and involves synthesis of a disaccharide unit on a lipid carrier, undecaprenyl phosphate. The lipid carrier is also involved in the synthesis of other components of the bacterial cell wall.

The first enzyme catalyses the transfer of phosphoryl-N-acetyl muramyl pentapeptide from UDP-MurNAc-pentapeptide to undecaprenyl phosphate with the simultaneous release of UMP. This enzyme is called phospho-N-acetylmuramyl-pentapeptide translocase (hereafter referred to as "the translocase") and is the product of the gene mraY in *Escherichia coli*. The product, undecaprenyl-pyrophosphate-N-acetylmuramylpentapeptide (Lipid-P-P-MurNAc-pentapeptide) or Lipid I or Lipid linked precursor I is the substrate for the second enzyme.

* N-acetylglucosaminyl transferase, transfers N-acetylglucosamine from UDP-GlcNAc (with simultaneous release of UDP) to form undecaprenyl-pyrophosphoryl-N-acetylmuramylpentapeptide-N-acetylglucosamine or Lipid II or Lipid linked precursor II. This enzyme is also called UDP-N-acetylglucosamine: N-acetylmuramyl(pentapeptide)-P-P-undecaprenyl-N-acetylgulosamine transferase (hereafter referred to as "the transferase"). The enzyme is the product of the gene murG in *Escherichia coli*. 

In the third stage, at the exterior of the cytoplasmic membrane, polymerisation of the glycan occurs. The disaccharide-pentapeptide unit is transferred from the lipid carrier to an existing disaccharide unit or polymer by a peptidoglycan transglycosylase (also referred to as a peptidoglycan polymerase) (hereafter referred to as "the transglycosylase"). The joining of the peptide bridge is catalyzed by peptidoglycan transpeptidase (hereafter referred to as "the transpeptidase"). Both enzyme activities which are essential reside in the same molecule, the penicillin binding proteins (or PBPs), as in PBP 1a or 1b in Escherichia coli. These are the products of the ponA and ponB genes respectively, in Escherichia coli.

There are several PBPs in the bacterial cell and these can be divided into two classes, the low molecular mass (LMM) and high molecular mass (HMM) PBPs. Some of the HMM PBPs are bifunctional enzymes having both transpeptidase and transglycosylase activity. Of the HMM PBPs, PBP2 and PBP3 and either PBP1A or PBP1B of E. coli have been shown to be essential for cell viability. The LMM PBPs appear to be important but not essential for cell growth (e.g. PBPs 4, 5, 6 of E. coli can be deleted resulting in growth defects but the cell survives, see S.A. Denome, P.K. Elf, T.A. Henderson , D.E. Nelson and K.D. Young, J. Bacteriol., (1999), 181(13), 3981-3993).

On transfer of the disaccharide-pentapeptide unit from the lipid precursor to an existing peptidoglycan chain the lipid is released as a molecule of undecaprenyl pyrophosphate. This has to be cleaved by a bacitracin-sensitive undecaprenyl pyrophosphorylase, also called undecaprenyl pyrophosphorylase or C55-isoprenyl pyrophosphorylase (hereafter referred to as the "lipid pyrophosphorylase") to generate undecaprenyl phosphate which can then re-enter the cycle at the second stage.

Both the transglycosylase and the transpeptidase enzymes (which reside within the high molecular weight penicillin binding proteins or PBPs) represent prime targets for drug discovery that have not been fully exploited due to the lack of suitable assays amenable to high throughput screening. Two antibiotics target these proteins: the glycopeptides and the beta-lactam antibiotics-penicillins and cephalosporins. The beta-lactam antibiotics, which inhibit the transpeptidase, are one of the most successful and have yielded many generations of drugs. Vancomycin, a glycopeptide, is an inhibitor of the transglycosylase and in many
cases of drug resistance is the last resort for treatment of bacterial infections. It is thus thought that new inhibitors of the transglycosylase and transpeptidase will be as successful and could become clinically useful antibiotics.

A conventional enzyme assay for the transglycosylase involves using radiolabelled Lipid II as substrate and monitoring incorporation of the radiolabel into peptidoglycan which is monitored by paper chromatography. In the paper chromatogram, peptidoglycan stays at the origin whereas the substrate, Lipid II, runs with an Rf of ~0.9. However, the substrate for the transglycosylase, Lipid II, is very hard to isolate in quantities sufficient for high throughput assays; it is usually made by isolating Lipid I and incubating it with a source of transferase in the presence of radiolabelled UDP-GlcNAc so as to make radiolabelled Lipid II. In addition, the Lipid II is not water-soluble and reactions do not often take place in the solution phase but are carried out on Whatman 3mm paper. This makes the reaction conditions hard to control. Since the product of the enzymatic reaction has to be analysed by paper chromatography it is not suitable for high throughput screening.

An assay for the transglycosylase enzyme has recently been described by Mei-Chu Lo et al in J. Am. Chem. Soc., (2000), 122, 3540-3541, where Lipid II is made by incubating E. coli membranes with UDP-MurNAc-pentapeptide and radiolabelled UDP-GlcNAc in the presence of the detergent, Triton X-100, which is an inhibitor of the transglycosylase. In a subsequent step the Triton X-100 is removed by the addition of beads to allow the transglycosylase reaction to proceed. The removal of the Triton X-100 by beads is tedious and also subsequent analysis by paper chromatography or by filtration makes it inconvenient for screening large numbers of test compounds.

WO 00/52035 describes a high throughput assay for the transglycosylase enzyme which is said to overcome the problems of the earlier methods (such as the difficulties of obtaining large quantities of Lipid II from natural sources and its handleability, e.g. being water-insoluble, as well as the use of paper chromatography). The assay relies on the use of chemically modified analogues of Lipid I and/or Lipid II (i.e. artificial substrates). The synthesis of artificial substrates does not necessarily make for an efficient and cost effective assay for screening test compounds. Furthermore, all of the Examples in WO 00/52035 appear to be theoretical and there is no actual data to support the suitability of the assay for high throughput screening. Indeed, the only assay that appears to have been carried out, the results of which are shown in Figure 7 of WO 00/52035, was one in which the product obtained was detected by paper chromatography.
It would be desirable to develop a method for assaying the activity of one or both of the transglycosylase and transpeptidase enzymes which is suitable for high throughput screening.

In accordance with the present invention, there is therefore provided a method of screening for potential anti-bacterial agents which comprises:

1. providing a membrane preparation obtained from a bacterial strain which may be deficient for peptidoglycan transglycosylase activity;
2. preparing a reaction mixture comprising the membrane preparation, a UDP-N-acetylmuramylpentapeptide (UDP-MurNAc-pentapeptide), radiolabelled UDP-N-acetyl glucosamine (UDP-GlcNAc), a source of divalent metal ions and, optionally, an inhibitor effective to inhibit further processing of undecaprenyl-pyrophosphoryl-N-acetylmuramylpentapeptide-N-acetylgalcosamine (Lipid II);
3. incubating the reaction mixture for a defined period under conditions suitable for Lipid II synthesis to occur;
4. adding to the reaction mixture of step (3),
   (a) either a substance to neutralise the inhibitor, or a source of peptidoglycan transglycosylase and a source of peptidoglycan transpeptidase, to allow further processing of Lipid II formed in step (3) toward peptidoglycan, and
   (b) a test compound;
5. after a defined period, terminating any further processing of Lipid II;
6. adding to the reaction mixture of step (5) a fluoroscer supported by, in or on a suitable substrate, and a detergent; and
7. measuring light energy emitted by the fluoroscer which is indicative of the presence of radiolabelled peptidoglycan.

Figure 1 is a graph showing the percentage inhibition of transglycosylase (and thus peptidoglycan synthesis) versus moenomycin concentration (after subtracting the corresponding 0% reaction readings).
Figure 2 is a graph showing the percentage inhibition of transglycosylase (and thus peptidoglycan synthesis) versus moenomycin concentration (after subtracting the corresponding 0% reaction readings).

5 Figure 3 is a graph showing the percentage inhibition of transglycosylase (and thus peptidoglycan synthesis) versus vancomycin concentration (after subtracting the corresponding 0% reaction readings).

Figure 4 is a graph showing the percentage inhibition of transpeptidase (and thus peptidoglycan synthesis) versus penicillin concentration (after subtracting the corresponding 0% reaction readings).

Figure 5 is a graph showing the percentage inhibition of transpeptidase (and thus peptidoglycan synthesis) versus ampicillin concentration (after subtracting the corresponding 0% reaction readings).

In the context of the present specification, it should be understood that the abbreviation "UDP" refers to uridine (5'-)diphosphate.

The method according to the present invention is very conveniently carried out using 96-well microtitre plates, thereby enabling a fast, simple and reproducible way of measuring enzyme activity.

The bacterial membranes may be prepared as described in Example 1 of WO 99/60155.

The membranes represent, *inter alia*, a source of undecaprenyl phosphate, a source of translocase enzyme and a source of transferase enzyme which are required to make Lipid II.

The quantity of membranes used will typically be in the range from 1 to 20µg, particularly from 4 to 6µg, protein per well of the microtitre plate.

Up until the end of step (3) of the method, peptidoglycan synthesis proceeds as far as the formation of Lipid II which is allowed to build-up in the reaction mixture. This build-up of Lipid II can be achieved in several ways which include the use of an inhibitor effective to
inhibit further processing of Lipid II (for example, an inhibitor of the transglycosylase enzyme such as vancomycin or moenomycin if the membrane preparation contains this enzyme); the use of membranes from a bacterial strain that is deficient for the transglycosylase enzyme activity (for example, as described in WO 96/16082); and the use of membranes prepared by a method involving treating bacterial cells firstly with lysozyme (for example, as described by Y. van Heijenoort et al., (1992), *J. Bacteriol.*, 174, 3549-3557).

In one embodiment of the invention, the membranes of *Escherichia coli* bacteria are used. Examples of *E. coli* strains that may be used include AMA1004 and AMA1004 ΔponB::Spc r (in which the gene ponB encoding PBP1b has been inactivated) as well as strains derived from the latter that have been transformed with an expression vector (e.g. a plasmid) comprising a homologous or heterologous gene encoding a penicillin binding protein.

The *E. coli* (mutant) strain AMA1004 ΔponB::Spc r is viable because of the presence of the ponA gene which encodes PBP1a having transglycosylase and transpeptidase activities. However, when using membranes from this strain, it is not necessary, for example, to employ an inhibitor of Lipid II further processing because it has been observed that, *in vitro*, under the assay conditions described here, PBP1a behaves as if it has no transglycosylase or transpeptidase activity.

Transformation of the above mutant strain with an expression vector containing a gene encoding a penicillin binding protein serves to counteract the transglycosylase deficiency of the mutant strain and thus build-up of Lipid II in step (3) of the method will require, for example, the presence of an inhibitor effective to inhibit further processing of Lipid II.

Transformed mutants are particularly advantageous if it is desired to screen compounds against a heterologous penicillin binding protein which might be unstable, or susceptible to inactivation by detergent or perhaps difficult to solubilise under the conditions employed in the method of the invention. Examples of such penicillin binding proteins include those of *Mycobacterium leprae* and *Mycobacterium smegmatis*. Methods for preparing the transformed mutants are described in the literature (see, for example, T. Tamura et al., (1980), *Proc. Natl. Acad. Sci. USA*, 77(8), 4499-4503).

The UDP-MurNAc-pentapeptide used may be any of those usually present in naturally-occurring peptidoglycans and is conveniently purified from bacteria or made enzymatically with precursors from bacteria, e.g. by methods similar to that described by T. den Blaauwen, M. Aarsman and N. Nanninga, *J. Bacteriol.*, (1990), 172, 63-70.)
In one embodiment of the invention, the UDP-MurNAc-pentapeptide used is UDP-MurNAc-L-alanine-γ-D-glutamic acid-m-diaminopimelic acid-D-alanine-D-alanine from Bacillus cereus.

The concentration of UDP-MurNAc-pentapeptide used per well of microtitre plate will typically be in the range from 5 μM to 300 μM, for example, from 5 μM, 10 μM, 15 μM, 20 μM or 25 μM up to and including 50 μM, 75 μM, 100 μM, 150 μM, 200 μM or 250 μM per well of the microtitre plate.

As radiolabelled UDP-N-acetyl glucosamine, it is convenient to use tritiated UDP-N-acetyl glucosamine (UDP-[3H]GlcNAc, commercially available from NEN-Dupont), at a concentration, for example, in the range from 0.25 μM, 0.5 μM, 1.0 μM, 2.5 μM, 4.2 μM or 5 μM up to and including 10 μM, 12.5 μM, 15 μM, 20 μM or 25 μM per well of the microtitre plate. Concentrations of radiolabelled UDP-N-acetyl glucosamine of 2.5 μM (with 0.1 to 0.5 μCi radioactivity per well) or 4.2 μM (with 0.6 to 1.2 μCi per well) have been advantageously used.

The divalent metal ions used are preferably magnesium ions. A suitable source of magnesium ions is magnesium chloride, for example at a concentration in the range from 5 to 30 mM, particularly from 10 to 25 mM, per well of microtitre plate.

The inhibitor effective to inhibit further processing of undecaprenyl-pyrophosphoryl-N-acetylmuramylpentapeptide-N-acetylg glucosamine (Lipid II) may conveniently be selected from known inhibitors of the transglycosylase enzyme which include vancomycin, ristocetin, moenomycin, mersacidin and actagardine. The amount of inhibitor used will depend on the inhibitor chosen and, in those instances where the inhibitor is capable of inhibiting other enzymes involved in peptidoglycan synthesis, the amount of inhibitor used will be chosen such that the transglycosylase is selectively inhibited. For example, it has been found that vancomycin (which is capable of inhibiting the translocase and transferase enzymes in addition to the transglycosylase enzyme) may be advantageously used at a concentration in the range from 10 to 200 μM, particularly from 30 to 100 μM or from 40 to 60 μM, per well of microtitre plate to selectively inhibit the transglycosylase.

In step (2) of the method, it may be convenient to use an aqueous medium such as a buffer solution, e.g. of HEPES-ammonia, HEPES- KOH (HEPES being N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) or Tris[hydroxymethyl]aminomethane hydrochloride ("Tris-HCl"), the buffer solution
having a pH of about 7.5. HEPES and Tris-HCl are commercially available from the Sigma-Aldrich Company Limited.

The reaction mixture prepared in step (2) is incubated in step (3) at a temperature in the range from, for example, 20°C to 37°C for a period in the range from, for example, 2, 3, 4, 5, 10, 20, 30, 40 or 50 minutes up to and including 100, 110, 120, 130, 140 or 150 minutes, under conditions suitable for enzyme-catalysed Lipid II synthesis to occur.

In step (4) of the invention, the conversion of Lipid II towards cross-linked peptidoglycan is initiated. If an inhibitor of Lipid II further processing is present in the reaction mixture, a substance is added in order to neutralise it and so make it ineffective. For example, if the inhibitor used is vancomycin, this may conveniently be achieved by adding a substance containing a terminal D-Ala-D-Ala dipeptide to which vancomycin is known to bind such as the tripeptide Lys-D-Ala-D-Ala or UDP-MurNAc-pentapeptide. The former is preferred since it is not also a reagent. The neutralising substance will conveniently be added as a molar excess (relative to the molar amount of inhibitor).

Alternatively, if there are no active or effective transglycosylase and transpeptidase enzymes present in the reaction mixture (as, for example, when using membranes from the above mutant strain of E. coli), then they will need to be added in step (4); this is further illustrated in the experimental section. For example, a purified homologous or heterologous penicillin binding protein containing both transglycosylase and transpeptidase activities, or a solubilised fraction of membranes (including those from a transformed mutant as described above) containing a protein(s) with transglycosylase and transpeptidase activities may be added.

In step (4), a test compound having potential antibacterial properties is added, typically in an aqueous solution of dimethyl sulphoxide.

The reaction mixture of step (4) is incubated for a further period at a temperature in the range from, for example, 20°C to 37°C. The incubation period will normally be shorter than the incubation period for the reaction mixture of step (3), e.g. in the range from 1, 5 or 10 minutes up to and including 20, 25 or 30 minutes.

Once the incubation period has come to an end, any further processing of Lipid II is terminated in step (5). This may be achieved by any suitable means. In one embodiment of the invention, a suitable amount of a divalent metal ion chelator compound is added, e.g. ethylenediaminetetraacetic acid (EDTA) (commercially available from the Sigma-Aldrich Company Limited). The concentration of the chelator compound will of course depend on the
particular chelator compound used. In the case of EDTA, the molar concentration will be at least half, preferably from 1.5 to 2 times, the molar concentration of divalent metal ions used.

In step (6), a fluorescer supported by, in or on a suitable substrate is added along with a detergent to the reaction mixture.

The detergent is any agent that is capable of emulsifying oil and/or acts as a wetting agent or surfactant. Examples of detergents that may be used include Triton X-100 (t-octylphenoxypolyethoxyethanol), Tween 20 (polyoxyethylenesorbitan monolaurate), Tween 80 (polyoxyethylenesorbitan monooleate), octyl-β-glycoside, CHAPS (3-[3-cholamidopropyl]dimethylammonio]-1-propane-sulphonate), Brij-35 (polyoxyethylene lauryl ether) and Sarkosyl (sodium lauryl sarcosinate).

The fluorescer used may be any of those routinely employed in scintillation proximity assays. The fluorescer is associated with or supported by, in or on a substrate, for example, lectin-coated beads, RNA-binding beads, anti-mouse antibody coated PVT (polymethylglycol) beads or wheatgerm agglutinin-coated PVT beads, all of which beads are commercially available from Amersham Inc. The substrate (e.g. beads) chosen should be capable of binding to bacterial cell walls.

In one embodiment of the invention, lectin-coated beads (particularly wheatgerm agglutinin-coated beads) impregnated with a fluorescer are used, for example, as described in US Patent No. 4,568,649 and European Patent No. 154,734. The beads (known as "Scintillation Proximity Assay" (or SPA) beads) are commercially available from Amersham Inc.

The beads (with fluorescer), which are conveniently added in the form of an aqueous suspension, are contacted with the reaction mixture of step (5) for a period of at least 10 minutes, preferably 3 to 10 hours or more (e.g. overnight), before the plate is "counted" in step (7), e.g., in a "Microbeta Tilux" counter.

Without being bound to any particular theory, it is believed that through the binding of the substrate to bacterial cell wall material (e.g. wheatgerm agglutinin-coated SPA beads are capable of binding sugar molecules, specifically N-acetyl glucosamine, present in bacterial cell wall material), radiolabelled crosslinked peptidoglycan formed in step (4) is brought into close proximity with the fluorescer which becomes activated by the radiation energy, resulting in the emission of light energy which is measured in step (7). Thus, light emitted from the fluorescer is believed to be indicative of the formation of cross-linked peptidoglycan.
The present invention will now be further explained by reference to the following illustrative examples in which the abbreviation HEPES refers to N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid].
Example 1

(i) Formation of radiolabelled Lipid II

The wells of a microtitre plate were individually filled with 15 μl of a solution containing 4 μg of *Escherichia coli* AMA1004 cell membranes prepared as described in WO 99/60155 (the membranes provided a source of translocase, transferase, transglycosylase, transpeptidase, lipid pyrophosphorylase and undecaprenyl phosphate), 15 μM UDP-MurNAc-L-alanine-γ-D-glutamic acid-m-diaminopimelic acid-D-alanine-D-alanine, 4.2 μM tritiated UDP-N-acetyl glucosamine (0.6 μCi - 1.2 μCi per well), 40 μM vancomycin (inhibitor of the transglycosylase), 50 mM HEPES-ammonia buffer pH 7.5, and 10 mM magnesium chloride (MgCl₂). The microtitre plate was incubated at 37°C for 120 minutes.

(ii) Formation of radiolabelled peptidoglycan

To each well was then added 10 μl containing 50 mM HEPES-ammonia buffer pH 7.5, 10 mM MgCl₂, UDP-N-acetyl glucosamine to a final concentration (in 25 μl) of 250 μM, a tripeptide to neutralise the vancomycin inhibitor: NαNe, diacetyl-Lys-D-Ala-D-Ala to a final concentration of 400 μM (in 25 μl; available from Sigma–Aldrich Company Limited, catalogue number D-9904), and 2 μl of test compound (moenomycin, a known transglycosylase inhibitor) in dimethyl sulphoxide (DMSO). The microtitre plate was then incubated at 37°C for 5 minutes and thereafter 75 μl of 6 mM ethylenediaminetetraacetic acid (EDTA) was added to stop any further peptidoglycan synthesis.

(iii) Detecting radiolabelled peptidoglycan

Following addition of the EDTA, there was added to each well 100 μl of an aqueous suspension of wheatgerm agglutinin-coated scintillation proximity assay beads comprising 500 μg beads in a solution of 50 mM HEPES-ammonia buffer pH 7.5 containing 0.4% “Sarkosyl” detergent (sodium lauryl sarcosinate) so that the final concentration of “Sarkosyl” detergent (in 200 μl) was 0.2%.

The microtitre plate was left for 3 to 10 hours at room temperature before being counted in the "Microbeta Trilux" counter.
Four wells of the microtitre plate were used as controls: two wells had EDTA and 10 µl water added at the end of (i) (0% reaction controls) and a further two wells contained no test compound (100% reaction controls).

The results are shown in Figure 1.

**Example 2**

The method described in Example 1 was repeated except that in (i) the membranes used were those of an *Escherichia coli* mutant, AMA1004 ΔponB::Spc^r^, a mutant from which the gene ponB encoding PBP1b has been inactivated, as described by S.Y. Yousif, J.K. Broome-Smith and B.G. Spratt, *J. Gen. Microbiol.*, (1985), 131, 2839-2845. These membranes lacked PBP1b activity which is the major transglycosylase in *Escherichia coli* and thus there was no need to add any vancomycin inhibitor.

In (ii), the tripeptide was replaced by an extract containing PBP1b, a source of transglycosylase and transpeptidase enzymes, obtained from the membranes of *Escherichia coli* AMA1004 ΔponA; PBS96. In this strain of *E. coli*, the ponA gene encoding PBP1a is inactivated and the ponB gene encoding PBP1b is overexpressed since the strain contains a plasmid comprising a further copy of ponB under the control of its native promoter.

The membranes of this *E. coli* strain were prepared as described in WO 99/60155. They were then treated with a detergent, 1% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulphonate (CHAPS), and 1M NaCl at a protein concentration of 5 mg/ml for 1 hour at room temperature. The mixture was then centrifuged at 150,000 x g for 15 minutes in a Beckman table top ultracentrifuge and the supernatant containing PBP1b collected. The quantity of PBP1b protein used was the "soluble fraction" equivalent to 0.75 µg of starting membrane and an excess of 1% w/v CHAPS, 1M NaCl solution was added such that the final concentration (in 25 µl) was 0.04% w/v CHAPS, 40 mM NaCl.

Four test compounds were used in (ii): moenomycin, vancomycin, penicillin and ampicillin, the first two being known transglycosylase inhibitors and the second two being known transpeptidase inhibitors.
Four wells of the microtitre plate were used as controls: in two wells 1 μl of 1% w/v CHAPS, 1M NaCl was added instead of the solubilised membrane, so that the final concentration (in 25 μl) was 0.04% w/v CHAPS, 40 mM NaCl (0% reaction controls) and a further two wells contained no test compound (100% reaction controls).

The microtitre plate in (ii) was incubated at 37°C for 20 minutes before addition of the EDTA.

The results are shown in Figures, 2, 3, 4 and 5.

Example 3

(i) Formation of radiolabelled Lipid II

The wells of a microtitre plate are individually filled with a total volume of 15 μl of a solution containing 4 μg cell membranes of Escherichia coli mutant, AMA1004 ΔponB::Sp cep when transformed with a plasmid comprising either the ponA gene and expressing PBP1a or the ponB gene and expressing PBP1b, 40 μM vancomycin, 15 μM UDP-MurNAc-L-alanine-γ-D-glutamic acid-m-diaminopimelic acid-D-alanine-D-alanine, 2.5 μM tritiated UDP-N-acetyl glucosamine (0.1 μCi per well), 50 mM HEPES-ammonia buffer pH 7.5, and 10 mM magnesium chloride (MgCl₂).

The microtitre plate is incubated at 37°C for 120 minutes.

(ii) Formation of radiolabelled peptidoglycan

To each well is then added 10 μl containing 50 mM HEPES-ammonia buffer pH 7.5, 10 mM MgCl₂, UDP-N-acetyl glucosamine to a final concentration (in 25 μl) of 250 μM, a tripeptide to neutralise the vancomycin inhibitor: NαNe, diacetyl-Lys-D-Ala-D-Ala to a final concentration of 400 μM (in 25 μl; available from Sigma–Aldrich Company, catalogue number D-9904), and 2 μl of test compound in dimethyl sulphoxide (DMSO).
The microtitre plate is then incubated at 37°C for 5 minutes and thereafter 75 µl of 6 mM ethylenediaminetetraacetic acid (EDTA) is added to stop any further peptidoglycan synthesis.

5 (iii) **Detecting radiolabelled peptidoglycan**

Following addition of the EDTA, there is added to each well 100 µl of an aqueous suspension of wheatgerm agglutinin-coated scintillation proximity assay beads comprising 500 µg beads in a solution of 50 mM HEPES-ammonia buffer pH 7.5 containing 0.4% “Sarkosyl” detergent (sodium lauryl sarcosinate) so that the final concentration of “Sarkosyl” detergent (in 200 µl) is 0.2%.

The microtitre plate is left for 3 to 10 hours at room temperature before being counted in the "Microbeta Trilux" counter.

15 Four wells of the microtitre plate are used as controls: two wells have EDTA and 10 µl water added at the end of (i) (0% reaction controls) and a further two wells contain no test compound (100% reaction controls).
CLAIMS

1. A method of screening for potential anti-bacterial agents which comprises:
   (1) providing a membrane preparation obtained from a bacterial strain which may be
deficient for peptidoglycan transglycosylase activity;
   (2) preparing a reaction mixture comprising the membrane preparation, a UDP-N-
acetylmuramylpentapeptide, radiolabelled UDP-N-acetyl glucosamine, a source of divalent
metal ions and, optionally, an inhibitor effective to inhibit further processing of undecaprenyl-
pyrophosphoryl-N-acetylmuramylpentapeptide-N-acetyl glucosamine (Lipid II);
   (3) incubating the reaction mixture for a defined period under conditions suitable for
Lipid II synthesis to occur;
   (4) adding to the reaction mixture of step (3),
      (a) either a substance to neutralise the inhibitor, or a source of peptidoglycan
transglycosylase and a source of peptidoglycan transpeptidase, to allow further processing of
Lipid II formed in step (3) toward peptidoglycan, and
      (b) a test compound;
   (5) after a defined period, terminating any further processing of Lipid II;
   (6) adding to the reaction mixture of step (5) a fluorescent supported by, in or on a suitable
substrate, and a detergent; and
   (7) measuring light energy emitted by the fluorescent which is indicative of the presence of
radiolabelled peptidoglycan.

2. A method according to claim 1, wherein the UDP-N-acetylmuramylpentapeptide is
UDP-MurNAc-L-alanine-\gamma-D-glutamic acid-m-diaminopimelic acid-D-alanine-D-alanine.

3. A method according to claim 1 or claim 2, wherein the source of divalent metal ions is
magnesium chloride.

4. A method according to any one of claims 1 to 3, wherein the inhibitor, if present, is a
transglycosylase inhibitor.

5. A method according to any one of claims 1 to 4, wherein the bacterial strain is a strain
of *Escherichia coli*. 
6. A method according to claim 5, wherein the *Escherichia coli* strain is AMA1004 or AMA1004 Δ*ponB::Spcr*.

7. A method according to claim 6, wherein the *Escherichia coli* strain AMA1004 Δ*ponB::Spcr* is transformed with an expression vector comprising a homologous or heterologous gene encoding a penicillin binding protein.

8. A method according to any one of claims 1 to 7, wherein the fluorescer is supported by, in or on lectin-coated beads.

9. A method according to any one of claims 1 to 8, wherein the detergent is selected from Triton X-100 and Sarkosyl.

10. A method according to any one of claims 1 to 9, wherein the test compound is an antagonist of one or both of the transglycosylase and the transpeptidase.

11. A compound which is an antagonist of one or both of peptidoglycan transglycosylase and peptidoglycan transpeptidase when identified by a method according to any one of claims 1 to 10.

12. A pharmaceutical composition comprising a compound according to claim 11 and a pharmaceutically acceptable carrier, adjuvant or diluent.

13. A method for the production of a pharmaceutical composition comprising the steps of carrying out a screening method according to claim 10 and mixing the compound identified with a pharmaceutically acceptable carrier, adjuvant or diluent.
Figure 2
Figure 4
Figure 5
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

| IPC 7 | C12Q1/48 | A61P31/00 | C12Q1/18 |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

| IPC 7 | C12Q |

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 99 60155 A (PRAHLAD DWARAKANATH; DE SOUSA SUNITA (IN); ASTRA AB (SE)) 25 November 1999 (1999-11-25) <em>page 5, line 21 - page 6, line 3; page 6, paragraph 4; claims 1 - 9</em></td>
<td>1-10,13</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

---

* Special categories of cited documents:
  * A* document defining the general state of the art which is not considered to be of particular relevance
  * E* earlier document but published on or after the international filing date
  * L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  * O* document referring to an oral disclosure, use, exhibition or other means
  * P* document published prior to the international filing date but later than the priority date claimed
  * X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  * Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
  * S* document member of the same patent family

Date of the actual completion of the international search

2 May 2003

Date of mailing of the international search report

20/05/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentboulevard 2 NL - 2280 HV Hilvink Tel (+31-70) 340-2040, Tx 31651 epo nl, Fax (+31-70) 340-3018

Authorized officer
Thiele, U

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 00 10587 A (INCARA PHARMACEUTICALS CORP) 2 March 2000 (2000-03-02) page 6, paragraph 1</td>
<td>1-10,13</td>
</tr>
<tr>
<td>Y</td>
<td>EP 0 378 059 A (POTTER COLIN GERALD; WARNER GERALD TRUSCOTT (GB)) 18 July 1990 (1990-07-18) claim 1</td>
<td>1-10,13</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 01 94623 A (SOLAPURE SURESH ;DESOUZA SUNITA MARIA (IN); ASTRazeneca AB (SE)) 13 December 2001 (2001-12-13) <em>pages 8 - 11; claims</em></td>
<td>1-10,13</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 01 94622 A (SOLAPURE SURESH ;DESOUZA SUNITA MARIA (IN); ASTRazeneca AB (SE)) 13 December 2001 (2001-12-13) <em>page 4, paragraph 4; page 6, bottom paragraph; claims</em></td>
<td>1-10,13</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. □ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. ✗ Claims Nos.: 11, 12 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
   see FURTHER INFORMATION sheet PCT/ISA/210

3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

□ The additional search fees were accompanied by the applicant's protest.

□ No protest accompanied the payment of additional search fees.
Continuation of Box I.2

Claims Nos.: 11,12

Claims 11 and 12 refer to compounds identified by a method according to any one of claims 1 - 10. The said compounds are not identified by means of their technical features. The subject-matter of claims 11 and 12 thus encompasses known compounds which are known to display the required antagonist activity (see present description, page 12, lines 31 - 33), known compounds with the hitherto unknown properties and compounds still to be made/detected. This situation gives rise to an unclarity concerning the scope of the claims and a lack of support to such an extent that no meaningful search is possible (Art. 5, 6 PCT; Rule 6(3)(a) PCT).

The applicant’s attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 0194623 A 13-12-2001</td>
<td>AU 6448201 A 17-12-2001</td>
<td>AU 6448301 A 17-12-2001</td>
<td></td>
</tr>
<tr>
<td>WO 0194622 A 13-12-2001</td>
<td>AU 6448201 A 17-12-2001</td>
<td>AU 6448301 A 17-12-2001</td>
<td></td>
</tr>
</tbody>
</table>